As year-end nears, pharma groups plump up their pipelines

pharmaphorum December 18, 2025
Phil Taylor

There has been a flurry of new licensing deals in the last few days, with Bristol Myers Squibb, Sanofi, Pfizer, Roche, and little Yarrow Bioscience all adding to their R&D pipelines.

BMS’ antibody alliance

BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, and China, that involves near-term payments of $90 million with another $1.035 billion in potential development and commercial milestones.

Details of the pact are sketchy at the moment, but Harbour will work on ‘next-generation multi-specific antibodies’ on behalf of BMS, using its Harbour Mice fully human antibody technology platform, designed to produce drug candidates with enhanced therapeutic efficacy. Preliminary clinical trials on candidates emerging from the collaboration will...

Today's Sponsors

Today's Sponsor